Advaxis (NASDAQ: ADXS) announced two research projects involving the company's Lm Technology™ immunotherapy candidate ADXS-PSA, which is being developed for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE